Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Clovis’ development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from their use. Clovis believes this approach to precision medicine – to deliver the right dr
BOULDER, Colo.--(BUSINESS WIRE)--Jul. 19, 2017--
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter
2017 financial results on Wednesday, August 2, 2017, after the close of
the U.S. financial markets. Clovis’ senior management will host a
conference call and live audio webcast at 4:30 p.m. ET that day to
discuss the company’s results in greater detail.
The conference call is being webcast and can be accessed from the Clovis
BOULDER, Colo.--(BUSINESS WIRE)--Jun. 21, 2017--
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that the
underwriters of its recently announced public offering of its common
stock have exercised in full their option to purchase an additional
The offering, including the sale of the additional shares, is expected
to close on June 26, 2017, subject to customary closing conditions.
Clovis Oncology intends to use th...
BOULDER, Colo.--(BUSINESS WIRE)--Jun. 20, 2017--
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today the pricing of an
underwritten public offering of 3,409,091 shares of its common stock at
$88.00 per share, before underwriting discounts and commissions. The
size of the offering was upsized from $250 million to $300 million. In
addition, the underwriters have a 30-day option to purchase up to an
additional 511,363 shares of common stock from Clovis Onco...
Sign up to receive email alerts whenever Clovis Oncology, Inc. posts new information to the site. Just enter your email address and click Submit.
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.